Epstein Barr Virus Reactivation during COVID-19 Hospitalization Significantly Increased Mortality/Death in SARS-CoV-2(+)/EBV(+) than SARS-CoV-2(+)/EBV(−) Patients: A Comparative Meta-Analysis

<div>Forest plots of proportional and comparative MA, respectively. (a) Proportional MA using Freeman–Tukey (F–T) statistical approach to detect percentage of mortality in COVID-19 patients with reactivated EBV. The analysis was carried out using JBI SUMARI. The EBV reactivation data for Saade et al. [<a href="/journals/ijclp/2023/1068000/#B14">14</a>] was extracted from the database provided by the authors. (b) Subgroup analysis to address high heterogeneity found in Figure <a href="../fig2/#a">2(a)</a>. (c) Comparative meta-analysis using dichotomous data type, relative risk, confidence interval (CI), and Mantel–Haenszel (M–H) statistical method in COVID-19 patients with and without EBV.</div>

International Journal of Clinical Practice

fig2

Figure 2

Figure 2: Epstein Barr Virus Reactivation during COVID-19 Hospitalization Significantly Increased Mortality/Death in SARS-CoV-2(+)/EBV(+) than SARS-CoV-2(+)/EBV(−) Patients: A Comparative Meta-Analysis 

Figure 2 | Epstein Barr Virus Reactivation during COVID-19 Hospitalization Significantly Increased Mortality/Death in SARS-CoV-2(+)/EBV(+) than SARS-CoV-2(+)/EBV(−) Patients: A Comparative Meta-Analysis 